Abstract
Clinical management of patients with malignant tumors has dramatically changed over the last years with the introduction of novel therapeutics, such as receptor-targeted therapies, downstream effectors and antiangiogenic compounds. This has created a need to re-evaluate the existing criteria used to assess treatment response. Emerging diagnostic techniques, combining functional and structural data may play a relevant role in planning new treatment strategies in individual cancer patients. In the new scenario where biological treatment results in stable disease, standard Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria have limitations. Moreover, functional 18-fluorodeoxyglucose ( 18FDG)-positron emission tomography (PET) imaging provides an additional tool to assess tumor activity, particularly consistent in some settings, such as Gastro Intestinal Solid Tumors (GIST), hepatocarcinoma, nonsmall lung cancer, and colorectal cancer. The integration of 18FDG-PET and computed tomography (CT) enhances the evaluation of oncologic patients treated with molecularly targeted drugs, and accelerates drug development in many types of tumors.
| Original language | English |
|---|---|
| Pages (from-to) | 259-265 |
| Number of pages | 7 |
| Journal | Reviews on Recent Clinical Trials |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Sep 2011 |
Fingerprint
Keywords
- CT
- PET
- RECIST 1.1 criteria
- RECISTcriteria
- Solid tumors
- Targeted-therapies
ASJC Scopus subject areas
- Medicine(all)
- Pharmacology
Cite this
Targeted-therapy and imaging response : A new paradigm for clinical evaluation? / Milano, Amalia; Perri, Francesco; Ciarmiello, Andrea; Caponigro, Francesco.
In: Reviews on Recent Clinical Trials, Vol. 6, No. 3, 09.2011, p. 259-265.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeted-therapy and imaging response
T2 - A new paradigm for clinical evaluation?
AU - Milano, Amalia
AU - Perri, Francesco
AU - Ciarmiello, Andrea
AU - Caponigro, Francesco
PY - 2011/9
Y1 - 2011/9
N2 - Clinical management of patients with malignant tumors has dramatically changed over the last years with the introduction of novel therapeutics, such as receptor-targeted therapies, downstream effectors and antiangiogenic compounds. This has created a need to re-evaluate the existing criteria used to assess treatment response. Emerging diagnostic techniques, combining functional and structural data may play a relevant role in planning new treatment strategies in individual cancer patients. In the new scenario where biological treatment results in stable disease, standard Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria have limitations. Moreover, functional 18-fluorodeoxyglucose ( 18FDG)-positron emission tomography (PET) imaging provides an additional tool to assess tumor activity, particularly consistent in some settings, such as Gastro Intestinal Solid Tumors (GIST), hepatocarcinoma, nonsmall lung cancer, and colorectal cancer. The integration of 18FDG-PET and computed tomography (CT) enhances the evaluation of oncologic patients treated with molecularly targeted drugs, and accelerates drug development in many types of tumors.
AB - Clinical management of patients with malignant tumors has dramatically changed over the last years with the introduction of novel therapeutics, such as receptor-targeted therapies, downstream effectors and antiangiogenic compounds. This has created a need to re-evaluate the existing criteria used to assess treatment response. Emerging diagnostic techniques, combining functional and structural data may play a relevant role in planning new treatment strategies in individual cancer patients. In the new scenario where biological treatment results in stable disease, standard Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria have limitations. Moreover, functional 18-fluorodeoxyglucose ( 18FDG)-positron emission tomography (PET) imaging provides an additional tool to assess tumor activity, particularly consistent in some settings, such as Gastro Intestinal Solid Tumors (GIST), hepatocarcinoma, nonsmall lung cancer, and colorectal cancer. The integration of 18FDG-PET and computed tomography (CT) enhances the evaluation of oncologic patients treated with molecularly targeted drugs, and accelerates drug development in many types of tumors.
KW - CT
KW - PET
KW - RECIST 1.1 criteria
KW - RECISTcriteria
KW - Solid tumors
KW - Targeted-therapies
UR - http://www.scopus.com/inward/record.url?scp=80051763253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051763253&partnerID=8YFLogxK
U2 - 10.2174/157488711796575540
DO - 10.2174/157488711796575540
M3 - Article
VL - 6
SP - 259
EP - 265
JO - Reviews on Recent Clinical Trials
JF - Reviews on Recent Clinical Trials
SN - 1574-8871
IS - 3
ER -